Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-GPC3 CAR-T cell immunotherapy
- Development stage
- Discontinued
- Lead developer
- Fuda Cancer Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
An autologous chimeric antigen receptor (CAR) T-cell therapy targeting Glypican-3 (GPC3), developed by Fuda Cancer Hospital in Guangzhou for the treatment of hepatocellular carcinoma (HCC). GPC3 is a cell-surface protein overexpressed in the majority of HCC cases but not in normal liver tissue, making it an ideal target for immunotherapy. The therapy involves the ex vivo genetic modification of a patient's T cells to express a CAR that recognizes GPC3, which, upon re-infusion, directs the T cells to identify and eliminate GPC3-positive tumor cells. Clinical development included Phase 1/2 trials, though these have been withdrawn or suspended.
- Other names
- GPC3-targeted CAR-T cell therapyGPC-3-targeted CAR-T cell therapyGPC 3-targeted CAR-T cell therapyChimeric Antigen Receptor-Modified T Cell Immunotherapy for Hepatocellular Carcinoma Targeting Glypican-3
02
Targets
CD3 (T-cell surface glycoprotein CD3)GPC3 (Glypican-3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on anti-GPC3 CAR-T cell immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-GPC3 CAR-T cell immunotherapy.